ARAlicia Rivera

Alicia Rivera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alicia Rivera has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Activation of the Renin-Angiotensin II-Aldosterone-System leads to increases in extracellular protein disulfide isomerase: role in insulin resistance

    by Ricardo Perez-Fuentes, Patricia Pulido, Joshua Cazares, Yaritza Inostroza-Nieves, Enrique Torres-Rasgado, Akira Nishiyama, Alicia Rivera, Rudy Ortiz, Jose Romero

    Insulin resistance and type II diabetes (T2D) are associated with activation of the Renin-Angiotensin-Aldosterone-System (RAAS) in part via regulation of its principal effector molecule, Angiotensin II (AngII). Endothelial cell activation leads to, among other factors, increased extracellular protein disulfide isomerase (PDI), a multifunctional protein that is critical to thrombus formation and regulation of reactive oxygen species. However, the effects of RAAS on PDI are unknown. We studied the in vitro effects of AngII on EA.hy926 human endothelial cells and measured PDI activity. Our results show that AngII (10 nM), dose- and time-dependently, increased PDI activity (Pn=6); an event that was blocked by pre-incubation with 0.5 μM losartan, an AngII Type I receptor antagonist (ARB). Western blot analyses showed increased PDI following AngII that was likewise reduced by losartan. In normal in Sprague–Dawley rats, we studied the in vivo effects of exogenous AngII infusion and observed significant increases in plasma PDI levels (P5) that were blunted by ARB treatment. We then studied the obese Otsuka Long Evans Tokushima Fatty (OLETF) (n=6/group) rats, a model of naturally increased AngII and RAAS-mediated insulin resistance and hypertension. Our results show that OLETF rats had increased insulin resistance and greater circulating PDI activity than lean control rats (PPP=0.496, Pn=134) and was significantly greater in T2D patients than healthy controls (Pn=56 vs 78, respectively). Our data in human and animal models suggest that RAAS activation represents a novel mechanism for PDI secretion. Thus we posit that PDI may contribute to the deleterious effects of RAAS-mediated vascular disease.

  • Open Access

    Endothelin‐1 receptor antagonists regulate cell surface‐associated protein disulfide isomerase in sickle cell disease

    by Gregory N. Prado, Jose R. Romero, Alicia Rivera

    Increased endothelin‐1 (ET‐1) levels, disordered thiol protein status, and erythrocyte hydration status play important roles in sickle cell disease (SCD) through unresolved mechanisms. Protein disulfide isomerase (PDI) is an oxidoreductase that mediates thiol/disulfide interchange reactions. We provide evidence that PDI is present in human and mouse erythrocyte membranes and that selective blockade with monoclonal antibodies against PDI leads to reduced Gardos channel activity (1.6±0.03 to 0.56±0.02 mmol·10 13 cell –1 ·min –1 , P< 0.001) and density of sickle erythrocytes (D 50 : 1.115±0.001 to 1.104±0.001 g/ml, P =0.012) with an IC 50 of 4 ng/ml. We observed that erythrocyte associated‐PDI activity was increased in the presence of ET‐1 (3.1 ± 0.2 to 5.6 ± 0.4%, P in vivo treatment of BERK sickle transgenic mice with ET‐1 receptor antagonists lowered circulating and erythrocyte associated‐PDI activity (7.1±0.3 to 5.2±0.2%, P FASEB J . 27, 4619–4629 (2013). www.fasebj.org


  • Parathyroid hormone ablation alters erythrocyte parameters that are rescued by calcium‐sensing receptor gene deletion

    by Jose R. Romero, Rodeler Youte, Edward M. Brown, Martin R. Pollak, David Goltzman, Andrew Karaplis, Lie‐Chin Pong, Lawrence Chien, Naibedya Chattopadhyay, Alicia Rivera

    The mechanisms by which parathyroid hormone (PTH) produces anemia are unclear. Parathyroid hormone secretion is regulated by the extracellular Ca2+‐sensing receptor. We investigated the effects of ablating PTH on hematological indices and erythrocytes volume regulation in wild‐type, PTH‐null, and Ca2+‐sensing receptor‐null/PTH‐null mice. The erythrocyte parameters were measured in whole mouse blood, and volume regulatory systems were determined by plasma membrane K+ fluxes, and osmotic fragility was measured by hemoglobin determination at varying osmolarities. We observed that the absence of PTH significantly increases mean erythrocyte volume and reticulocyte counts, while decreasing erythrocyte counts, hemoglobin, hematocrit, and mean corpuscular hemoglobin concentration. These changes were accompanied by increases in erythrocyte cation content, a denser cell population, and increased K+ permeability, which were in part mediated by activation of the K+/Cl− cotransporter and Gardos channel. In addition we observed that erythrocyte osmotic fragility in PTH‐null compared with wild‐type mice was enhanced. When Ca2+‐sensing receptor gene was deleted on the background of PTH‐null mice, we observed that several of the alterations in erythrocyte parameters of PTH‐null mice were largely rescued, particularly those related to erythrocyte volume, K+ fluxes and osmotic fragility, and became similar to those observed in wild‐type mice. Our results demonstrate that Ca2+‐sensing receptor and parathyroid hormone are functionally coupled to maintain erythrocyte homeostasis.


  • Ablation of the Kell/Xk complex alters erythrocyte divalent cation homeostasis

    by Alicia Rivera, Siok Yuen Kam, Mengfatt Ho, Jose R. Romero, Soohee Lee


  • Reduced sickle erythrocyte dehydration in vivo by endothelin-1 receptor antagonists

    by Alicia Rivera

    Elevated plasma levels of cytokines such as endothelin-1 (ET-1) have been shown to be associated with sickle cell disease (SCD). However, the role of ET-1 in the pathophysiology of SCD is not entirely clear. I now show that treatment of SAD mice, a transgenic mouse model of SCD, with BQ-788 (0.33 mg·kg−1·day−1 intraperitoneally for 14 days), an ET-1 receptor B (ETB) antagonist, induced a significant decrease in Gardos channel activity (1.7 ± 0.1 to 1.0 ± 0.4 mmol·1013 cell−1·h−1, n = 3, P = 0.019) and reduced the erythrocyte density profile by decreasing the mean density (D50; n = 4, P = 0.012). These effects were not observed in mice treated with BQ-123, an ET-1 receptor A (ETA) antagonist. A mixture of both antagonists induced a similar change in density profile as with BQ-788 alone that was associated with an increase in mean cellular volume and a decrease in corpuscular hemoglobin concentration mean. I also observed in vitro effects of ET-1 on human sickle erythrocyte dehydration that was blocked by BQ-788 and a mixture of ETB/ETA antagonists but not by ETA antagonist alone. These results show that erythrocyte hydration status in vivo is mediated via activation of the ETB receptor, leading to Gardos channel modulation in SCD.


  • Effect of complete protein 4.1R deficiency on ion transport properties of murine erythrocytes

    by Alicia Rivera, Lucia De Franceschi, Luanne L. Peters, Philippe Gascard, Narla Mohandas, Carlo Brugnara

    Moderate hemolytic anemia, abnormal erythrocyte morphology (spherocytosis), and decreased membrane stability are observed in mice with complete deficiency of all erythroid protein 4.1 protein isoforms (4.1−/−; Shi TS et al. J Clin Invest 103: 331, 1999). We have examined the effects of erythroid protein 4.1 (4.1R) deficiency on erythrocyte cation transport and volume regulation. 4.1−/− mice exhibited erythrocyte dehydration that was associated with reduced cellular K and increased Na content. Increased Na permeability was observed in these mice, mostly mediated by Na/H exchange with normal Na-K pump and Na-K-2Cl cotransport activities. The Na/H exchange of 4.1−/− erythrocytes was markedly activated by exposure to hypertonic conditions (18.2 ± 3.2 in 4.1−/− vs. 9.8 ± 1.3 mmol/1013 cell × h in control mice), with an abnormal dependence on osmolality (EC50 = 417 ± 42 in 4.1−/− vs. 460 ± 35 mosmol/kgH2O in control mice), suggestive of an upregulated functional state. While the affinity for internal protons was not altered (K0.5 = 489.7 ± 0.7 vs. 537.0 ± 0.56 nM in control mice), the Vmax of the H-induced Na/H exchange activity was markedly elevated in 4.1−/− erythrocytes ( Vmax 91.47 ± 7.2 compared with 46.52 ± 5.4 mmol/1013 cell × h in control mice). Na/H exchange activation by okadaic acid was absent in 4.1−/− erythrocytes. Altogether, these results suggest that erythroid protein 4.1 plays a major role in volume regulation and physiologically downregulates Na/H exchange in mouse erythrocytes. Upregulation of the Na/H exchange is an important contributor to the elevated cell Na content of 4.1−/− erythrocytes.


  • Abnormal regulation of Mg2+ transport via Na/Mg exchanger in sickle erythrocytes

    by Alicia Rivera, Ana Ferreira, Danielle Bertoni, José R. Romero, Carlo Brugnara

    Erythrocyte magnesium (Mg2+) deficiency has been demonstrated in sickle cell disease to contribute to erythrocyte dehydration, K loss, and thus sickling. No studies have assessed the functional properties of the Na/Mg exchanger in sickle cell disease. Using Mg2+-loaded erythrocytes, we measured Mg2+ efflux induced by extracellular Na+. We estimated that the Na/Mg exchanger had higher maximal velocity, higher affinity for Na+, and lower cooperativity for Mg2+ in sickle than in normal erythrocytes. The activity of the exchanger was markedly decreased by hypotonic and hypertonic conditions in normal erythrocytes but not in sickle erythrocytes. Studies of density-separated erythrocytes showed that the activity of the exchanger decreased as the mean cellular hemoglobin concentration increased in normal but not in sickle erythrocytes. Inhibition of protein kinase C (PKC) activity by calphostin C and chelerythrine increased the activity of the exchanger in normal but not in sickle erythrocytes. Inhibition of serine/threonine phosphatases did not affect the activity of the exchanger in either normal or sickle erythrocytes. Altogether, these data indicate that the Na/Mg exchanger is abnormally regulated in sickle erythrocytes. Therefore, Mg2+ depletion in sickle erythrocytes might be mediated by an up-regulated Na/Mg exchanger, possibly by dephosphorylation of the transporter or a closely associated regulator. (Blood. 2005;105:382-386)


    • 1 November 2004
      • Vol. 89  (11) , 1287-98

    In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia.

    by Lucia De Franceschi, Franco Turrini, Marek Honczarenko, Kojio Ayi, Alicia Rivera, Mark D Fleming, Terry Law, Franca Mannu, Frans A Kuypers, Aalt Bast, et al.

    Oxidant damage is an important contributor to the premature destruction of erythrocytes and anemia in thalassemias. To assess the extent of oxidant damage of circulating erythrocytes and the effects of antioxidant therapy on erythrocyte characteristics and anemia, we used a mouse model of human beta-thalassemia intermedia (b1/b2 deletion). Several parameters indicative of oxidant damage were measured at baseline and following administration of the semi-synthetic flavonoid antioxidant, 7-monohydroxyethylrutoside (monoHER), to beta-thalassemic mice at a dose of either 500 mg/kg i.p. once a day (n=6) or 250 mg/kg i.p. twice a day (n=6) for 21 days. Significant erythrocyte oxidant damage at baseline was indicated by: (i) dehydration, reduced cell K content, and up-regulated K-Cl co-transport; (ii) marked membrane externalization of phosphatidylserine; (iii) reduced plasma and membrane content of vitamin E; and (iv) increased membrane bound IgG. MonoHER treatment increased erythrocyte K content, and markedly improved all cellular indicators of oxidant stress and of lipid membrane peroxidation. While anemia did not improve, monoHER therapy reduced reticulocyte counts, improved survival of a fraction of red cells, and reduced ineffective erythropoiesis with decreased total bilirubin, lactate dehydrogenase and plasma iron. Antioxidant therapy reverses several indicators of oxidant damage in vivo. These promising antioxidant effects of monoHER should be investigated further.